Relmada data offer hope of safer option for depression

Relmada’s depression therapy may avoid the psychotomimetic effects of J&J’s esketamine, enabling at-home use

Relmada more than doubled its share price Tuesday after reporting Phase II data hinting that REL-1017 could be as effective at treating depression as J&J’s Spravato without the psychotomimetic side effects that require physician monitoring.

Relmada Therapeutics Inc. (NASDAQ:RLMD) shares gained $15.01 (134%) to $26.20 Tuesday before giving back

Read the full 489 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers